Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

729
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
729
Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating PSMA PET Radiopharmaceuticals: Clinical and Operational Factors.

AJR. American journal of roentgenology·2026
Same author

The Semicentenary Anniversary of FDG: A Momentous Milestone in Nuclear Medicine.

Clinical nuclear medicine·2026
Same author

Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.

PET clinics·2026
Same author

Update to the Appropriate Use Criteria for <sup>18</sup>F-FDG PET/CT for Initial Staging of Malignant Disease.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A Conversation Between the Honorable NRC Commissioner David A. Wright and ACMUI Chair Hossein Jadvar.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

ACR Appropriateness Criteria® Preprocedural Chest or Cardiac Imaging for Cardiothoracic Surgery.

Journal of the American College of Radiology : JACR·2026

Related Experiment Video

Updated: Mar 20, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Targeted Radionuclide Therapy: Practical Applications and Future Prospects.

Katherine Zukotynski1, Hossein Jadvar2, Jacek Capala3

  • 1Departments of Radiology and Medicine, McMaster University, Hamilton, ON, Canada.

Biomarkers in Cancer
|May 27, 2016
PubMed
Summary

Targeted radionuclide therapy offers personalized cancer treatment by tailoring treatments with radiation dosimetry and tumor response. Effective implementation requires multidisciplinary collaboration and addressing practical challenges for improved patient outcomes.

Keywords:
oncologyradionuclide therapytargeted

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Related Experiment Videos

Last Updated: Mar 20, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Science

Background:

  • Targeted radionuclide therapy has rapidly advanced, enabling personalized cancer treatment strategies.
  • Current approaches utilize clinical and imaging assessments for therapy selection and tailoring.
  • Personalized medicine maximizes therapeutic effects and minimizes toxicity but faces implementation challenges and high costs.

Purpose of the Study:

  • To highlight the advancements and challenges in targeted radionuclide cancer therapy.
  • To emphasize the need for multidisciplinary collaboration and practical considerations for successful implementation.
  • To discuss the potential of radiopharmaceuticals in predicting response and guiding treatment decisions.

Main Methods:

  • Review of recent developments in targeted radionuclide therapy.
  • Discussion of personalized medicine principles in cancer treatment.
  • Exploration of the role of radiopharmaceuticals as biomarkers.
  • Analysis of factors influencing successful adoption of targeted radionuclide therapy.

Main Results:

  • Personalized approaches enhance therapeutic efficacy and reduce toxicity.
  • Multidisciplinary collaboration is crucial for effective implementation.
  • Combining radiopharmaceuticals with conventional therapies may improve survival and reduce morbidity.
  • Radiopharmaceuticals are key biomarkers for predicting treatment response.

Conclusions:

  • Targeted radionuclide therapy represents a significant advancement in personalized cancer care.
  • Successful adoption requires addressing practical aspects like manufacturing, delivery, and reimbursement.
  • Interdisciplinary cooperation and the development of radiopharmaceutical biomarkers are essential for future success.
  • Combining targeted radionuclide therapy with conventional treatments shows promise for improved patient outcomes.